Nettle Root Extract vs Nettle Leaf Extract: What Buyers Should Verify Before Sourcing
A purchase order that reads "Nettle Extract 10:1" could describe a water-extracted leaf concentrate, an ethanol-extracted root preparation, or something in between. Root and leaf come from the same plant — but they are pharmacopoeially distinct raw materials with different quality markers, different phytochemical profiles and different areas of established use.
This guide walks through the specification differences that matter when you are sourcing, comparing quotations or writing an incoming-material specification for nettle extract.
Below: plant-part and species definitions, pharmacopoeial quality indicators, extract-preparation variables, research context for formulators and a pre-order checklist — all from the perspective of a B2B ingredient buyer.
Request a Sample → Jump to Checklist ↓01 Starting Point
"Nettle Extract" Is Not a Complete Raw-Material Specification
Stinging nettle (Urtica dioica L.) is one of the most widely traded botanical raw materials in the global supplement and personal-care supply chain. Yet quotations routinely omit critical specification fields.
Consider two supplier responses to the same RFQ:
| Field | Supplier A | Supplier B |
|---|---|---|
| Product name | Stinging Nettle Extract 10:1 | Stinging Nettle Extract 10:1 |
| Species | Urtica dioica L. | Urtica dioica / U. urens |
| Plant part | Leaf | Root |
| Extraction solvent | Water | Ethanol 60% |
| Marker compound | Chlorogenic acid (HPLC) | β-Sitosterol (HPLC) |
Both labels say "Nettle Extract 10:1." They are not equivalent. The plant part, species, solvent and marker compound are all different — and so is what the buyer will receive.
Specifying "nettle extract" on a purchase order without stating the plant part is like ordering "ginseng" without stating root or leaf. The products are not interchangeable.
The sections below explain each variable so that buyers can write a specification that leaves no room for ambiguity.
02 Raw Material Identity
Plant Part and Species Both Need to Be on the PO
Leaf, herb and root are pharmacopoeially distinct
European regulatory authorities do not treat "nettle" as a single raw material. The European Medicines Agency (EMA) maintains separate herbal monographs for three distinct nettle substances:
| Pharmacopoeial name | Definition | EMA traditional-use indications |
|---|---|---|
| Urticae folium (nettle leaf) | Dried leaves of U. dioica / U. urens | Minor articular pain; minor urinary complaints (supportive diuretic) |
| Urticae herba (nettle herb) | Dried aerial parts (leaves + stems) | Minor urinary complaints; minor articular pain; seborrhoeic skin conditions (external) |
| Urticae radix (nettle root) | Dried roots and rhizomes | Lower urinary tract symptoms related to benign prostatic hyperplasia (BPH) |
The EMA monographs are separate documents. Urticae radix has its own assessment report, most recently revised in 2025. The traditional-use indications do not overlap: root is directed towards BPH-related urinary symptoms, while leaf and herb are directed towards articular pain and supportive diuretic use.[1][2]
This matters for two practical reasons. First, the starting material determines the extract's phytochemical profile — leaf tissue and root tissue contain different classes of characteristic compounds (see Section 03). Second, for products registered or notified as traditional herbal medicinal products under the EU framework, the plant part stated in the dossier must match the relevant EMA monograph. Using leaf extract in a formulation referenced against the root monograph — or vice versa — creates a regulatory mismatch.
A common procurement scenario illustrates why this is not theoretical: a customer's PO reads "Nettle Herb Extract 10:1." The supplier ships nettle leaf extract. Both come from the aerial part of the plant, but "herb" (Urticae herba) includes stems while "leaf" (Urticae folium) does not. Under the EMA framework these are different starting materials with different monographs. Whether the buyer accepts the shipment depends on which specification their formulation is built against — and that conversation should happen before the order is placed, not at incoming QC.
Species: U. dioica and U. urens are both accepted
The European Pharmacopoeia (Ph. Eur.) monograph for Urticae folium accepts Urtica dioica L. (the common stinging nettle), Urtica urens L. (the small nettle) or a mixture of both species. The EMA root monograph likewise covers both species and their hybrids.[2][3]
Commercially, the vast majority of bulk nettle leaf extract derives from U. dioica. However, a quotation that simply says "Urtica" without the full binomial leaves the species open. For complete traceability — and to ensure batch-to-batch consistency — the purchase order should state the accepted species.
A quotation specifying Urtica dioica L. and one specifying Urtica dioica / U. urens are not identical specifications, even when both are acceptable under the Ph. Eur. framework.
Buyer's note
A minimum specification for any nettle extract PO should state at least: (1) species — U. dioica, U. urens, or mixture accepted; (2) plant part — leaf, herb (aerial parts) or root. Omitting either field means the supplier decides for you.
03 Quality Markers
What the Pharmacopoeias Measure — and What the Chemistry Tells You
Official quality-control markers
One of the clearest ways to see that root and leaf are different raw materials is to compare their official quality-control markers. Two well-known pharmacopoeial references set different requirements:
| Parameter | Nettle Leaf — Ph. Eur. Urticae folium | Nettle Root — USP Powdered Stinging Nettle Extract |
|---|---|---|
| Source | European Pharmacopoeia (Ph. Eur. 10th ed.) | United States Pharmacopeia (USP) |
| Defined plant part | Dried leaves of U. dioica / U. urens | Dried roots and rhizomes of U. dioica |
| QC marker compound(s) | Caffeoylmalic acid + chlorogenic acid (sum, expressed as chlorogenic acid) ≥ 0.3 % | Total amino acids ≥ 5.0 %; β-sitosterol ≥ 0.1 %; scopoletin ≥ 30 μg/g |
| Extract ratio | Raw-material monograph (not extract-specific) | 10 : 1 |
| Extraction solvent | — | 60 % alcohol or other suitable solvents |
Sources: Ph. Eur. monograph 01/2008:1897, confirmed by Koczkodaj et al. 2023[3][4]; USP Powdered Stinging Nettle Extract monograph[5].
The markers are chemically unrelated. Caffeoylmalic acid is a hydroxycinnamic acid derivative characteristic of the leaf. Scopoletin is a coumarin found predominantly in the root. These compounds serve as identity and quality markers — they help confirm that the correct plant part was used.
β-Sitosterol plays a different role in each context. The USP lists β-sitosterol ≥ 0.1 % as a quality-control marker for the root extract. However, the ESCOP monograph on Urticae radix notes that the actual sterol content in root preparations is generally very low (< 0.01 %) and considers lignans, polysaccharides and the lectin UDA as the principal constituents of pharmacological interest.[6] A QC marker used for identity or consistency purposes is not necessarily the same compound driving the pharmacological profile — an important distinction for formulators referencing COA data. We explore this topic in more detail in β-Sitosterol in Nettle Leaf Extract.
Commercial note
β-Sitosterol also appears as a commercial specification for nettle leaf extract. PhytoVale's own nettle leaf extract, for example, is offered in both ratio grades (10:1, 30:1, 50:1) and a standardised β-sitosterol 0.8 % grade (HPLC). This does not conflict with the USP root monograph — β-sitosterol is present in both parts of the plant, and a supplier may standardise on it for either. The key is to read the plant-part declaration alongside the marker.
Characteristic compound classes behind the markers
The official markers above sit within broader phytochemical profiles. The table below summarises the compound families that the analytical literature associates with each plant part — reported across multiple studies, not guaranteed in every commercial product.
| Compound class | Root | Leaf |
|---|---|---|
| Lignans | Secoisolariciresinol, neo-olivil, (−)-3,4-divanillyltetrahydrofuran | Not characteristic |
| Lectin | Urtica dioica agglutinin (UDA) | Present at lower levels |
| Polysaccharides | Acidic polysaccharides | Present |
| Coumarins | Scopoletin | Trace |
| Hydroxycinnamic acids | Not characteristic | Caffeoylmalic acid, chlorogenic acid, caffeic acid |
| Flavonoids | Minor | Rutin, quercetin glycosides, kaempferol glycosides |
| Phytosterols | β-Sitosterol, stigmasterol (low content) | β-Sitosterol (higher relative content) |
| Ceramides | Present | Not characteristic |
Sources: Chrubasik et al. 2007 (root review)[6]; Taheri et al. 2022 (comprehensive review)[7]; ESCOP monographs[8]; Ph. Eur.[3].
The practical take-away for procurement: if a COA cites scopoletin or amino-acid content, it most likely describes a root-derived product. If it cites caffeoylmalic acid, chlorogenic acid or total hydroxycinnamic acids, it describes a leaf-derived product. This can serve as a quick cross-check when the plant-part declaration on a COA is ambiguous or missing.
04 Extract Variables
Same Ratio Label, Different Extract
Even after confirming plant part and species, two products labelled "10:1" may still differ significantly. The EMA herbal monograph on Urticae folium lists several preparation types that have documented traditional or well-established use[1]:
| Preparation | DER (approximate) | Extraction solvent |
|---|---|---|
| Dry extract B | 4.7–6 : 1 | Water |
| Dry extract C | 5–10 : 1 | Water |
| Dry extract D | 8–10 : 1 | Ethanol 50 % (V/V) |
A "10:1" water extract and a "10:1" ethanol 50 % extract start from the same plant part but will have different extraction efficiencies for different compound classes. Water preferentially extracts polysaccharides, organic acids, minerals and water-soluble phenolics. Ethanol concentrates lipophilic components — phytosterols, certain flavonoid aglycones, chlorophyll-related compounds — more efficiently.
Two products labelled "Nettle Extract 10:1" are not necessarily equivalent — even before you compare price.
Beyond the ratio and solvent, buyers should also confirm:
Carrier or excipient. Many powdered extracts use maltodextrin or silicon dioxide as a processing aid. A "10:1" extract on maltodextrin and one with no carrier deliver different amounts of actual extractive material per kilogram.
Marker compound and assay method. A ratio-only specification (e.g. "10:1, no marker") tells you the input-to-output mass ratio but nothing about what the extract contains. A specification with an HPLC marker (e.g. β-sitosterol 0.8 %, HPLC) provides a verifiable, batch-specific quality anchor.
Raw botanical vs extract composition. Nettle leaves are documented to contain vitamin C, carotenoids, chlorophyll and a high mineral content.[7] These figures describe the fresh or dried leaf. A commercial ethanol extract will concentrate certain compounds and lose others — so compositional data for the raw leaf should not be cited as the specification for the extract.
For a closer look at what 10:1, 30:1 and 50:1 labels actually mean for nettle leaf — and how they compare with standardised grades — see Nettle Leaf Extract Ratio Grades Explained.
05 Research Context
What the Published Evidence Means for Sourcing Decisions
Buyers sourcing nettle extract for a specific end-use often want to understand the research landscape. The summaries below are framed by what the evidence means for procurement — not as health-claim guidance.
Root — BPH and lower urinary tract symptoms
This is the most clinically studied application for nettle root extract. Several randomised controlled trials have investigated root preparations in men with BPH-related lower urinary tract symptoms, including a crossover study of 558 patients that reported significant IPSS improvement compared with placebo.[9]
A 2025 systematic review (6 RCTs, 1,210 patients) using the GRADE framework found some promising signals — a modest improvement in IPSS (very low certainty evidence) and a reduction in PSA (low certainty evidence) — but noted that the overall certainty is limited by risk of bias, heterogeneity and imprecision.[10]
The combination of Serenoa repens (saw palmetto) fruit extract with Urtica dioica root extract is a classical pairing in European phytotherapy for BPH, referenced in multiple EMA and ESCOP documents.[6]
What this means for buyers: if you are sourcing root extract for a prostate-health formula intended for the EU market, the EMA traditional-use monograph provides a regulatory pathway that does not depend on clinical-trial-level proof. The clinical data supports the tradition but is not the basis for market access. For other markets, verify local registration requirements separately.
Leaf — anti-inflammatory mechanisms and seasonal allergies
A well-cited in-vitro study demonstrated that nettle leaf extract inhibits NF-κB, a central pro-inflammatory transcription factor (Riehemann et al. 1999).[11] A separate in-vitro investigation identified H1-receptor antagonism, inhibition of mast-cell tryptase, and COX-1/COX-2/HPGDS inhibition in a proprietary nettle leaf preparation (Roschek et al. 2009).[12]
One early randomised, double-blind trial (Mittman 1990; 98 enrolled, 69 completers) tested freeze-dried Urtica dioica leaf for allergic rhinitis. The global assessment at follow-up favoured nettle over placebo, but symptom-diary differences were only modest.[13]
The ESCOP monograph on Urticae folium/herba supports traditional use for adjuvant treatment of arthritis, arthroses and rheumatic conditions, and for enhancing renal elimination of water in inflammatory lower urinary tract complaints.[8]
What this means for buyers: the mechanistic rationale for nettle leaf in allergy-related pathways is of interest, but it rests on in-vitro data and one small, early clinical trial. Do not position the raw material as a clinically validated anti-allergy active without jurisdiction-specific claim review. For joint-health and diuretic formulations, the ESCOP and EMA traditional-use framework is the stronger regulatory footing.
Leaf — hair and scalp care (cosmetic use)
Nettle leaf extract is registered under the INCI name Urtica Dioica Extract and is widely used in hair-care and scalp-care formulations.
A 2023 in-vitro study on HaCaT keratinocytes reported that U. dioica leaf extract downregulated 5α-reductase type II gene expression — a pathway relevant to androgen-related skin and hair biology.[14] β-Sitosterol, one of the phytosterols present in the leaf, has separately been reported to stimulate VEGF synthesis in the context of hair-follicle angiogenesis.[15]
What this means for buyers: the INCI registration and established trade use are the primary commercial drivers for nettle leaf extract in personal care. The in-vitro research is supporting context for product-development conversations, not a standalone claim basis. Human clinical evidence for hair-growth efficacy specific to nettle leaf extract remains limited. For formulation guidance and usage rates, see Nettle Leaf Extract in Hair & Scalp Care Formulations.
06 Procurement
Before You Place the Order: A Buyer's Checklist
When comparing two or more nettle extract quotations — or writing an incoming-material specification — verify these fields:
| # | Specification field | Why it matters |
|---|---|---|
| 1 | Species (U. dioica, U. urens, or mixture) | Defines the botanical identity; not all suppliers state the full binomial |
| 2 | Plant part (leaf, herb, root) | Determines the phytochemical class and the applicable pharmacopoeial monograph |
| 3 | Extract ratio or DER | Indicates concentration; confirm whether it is a genuine DER or a nominal label |
| 4 | Extraction solvent (water, ethanol %, hydroalcoholic) | Affects which compounds are extracted; two "10:1" products made with different solvents are not equivalent |
| 5 | Carrier (maltodextrin, silicon dioxide, none) | A carrier dilutes the extractive content per kilogram; affects dosage calculation |
| 6 | Marker compound and assay method | An HPLC marker (e.g. β-sitosterol 0.8 %, caffeoylmalic acid) provides a verifiable quality anchor; a ratio-only spec does not |
| 7 | Plant-part declaration on the COA | Cross-check that the COA explicitly states the plant part — not just "Nettle Extract" |
A specification that omits any of these fields leaves room for receiving a product that does not match the intended formulation or regulatory requirement.
At PhytoVale, our nettle leaf extract COA states the species (Urtica dioica L.), the plant part (leaf), the extraction solvent (ethanol), the extract ratio and — for the standardised grade — a β-sitosterol assay by HPLC. Samples and COA are available on request.
07 FAQ
Frequently Asked Questions
A supplier offered nettle root extract as a substitute for the leaf extract I ordered — should I accept it?
Generally, no. Root and leaf have different characteristic compound classes, different pharmacopoeial quality markers and different areas of established use. Accepting a root substitute for a formulation designed around leaf extract means the phytochemical profile will not match what the formula was built on — and if the product is registered against an EMA leaf monograph, the substitution creates a regulatory mismatch. Treat it as a different raw material and re-evaluate against your specification.
Is nettle leaf extract the same as nettle herb extract?
"Nettle leaf" (Urticae folium) is the dried leaf only. "Nettle herb" (Urticae herba) is the dried aerial part — leaves plus stems. The EMA maintains separate monographs for each. They are similar but not identical starting materials; the herb includes stem tissue, which may alter the overall phytochemical balance. Check which one your formulation specification calls for.
Does β-sitosterol come from nettle root or nettle leaf?
Both parts contain β-sitosterol. The USP includes β-sitosterol ≥ 0.1 % as a quality marker for its powdered root extract monograph. Commercially, nettle leaf extract is also available standardised on β-sitosterol (e.g. 0.8 % by HPLC). The key is to confirm the plant-part declaration alongside the marker — β-sitosterol alone does not tell you which part of the plant was extracted.
What does "10:1" actually mean on a nettle extract specification?
A drug-extract ratio (DER) of 10:1 means approximately 10 kg of dried botanical raw material yielded 1 kg of finished extract. However, a ratio label does not specify the solvent used, whether a carrier was added or what compounds are present. Two "10:1" extracts made from the same plant part but with different solvents (e.g. water vs 50 % ethanol) will have different phytochemical profiles.
Which plant part is typically used in hair-care formulations?
Most cosmetic hair-care and scalp-care products use nettle leaf extract, registered under the INCI name Urtica Dioica Extract. Root extract is far less common in personal care; its commercial use centres on dietary supplements for prostate-health formulations.
What markers should I look for on a nettle leaf extract COA?
The European Pharmacopoeia requires dried nettle leaf to contain ≥ 0.3 % total caffeoylmalic acid + chlorogenic acid (expressed as chlorogenic acid). For a commercial leaf extract, common specifications include β-sitosterol content (HPLC) or silica content (for cosmetic grades). A ratio-extract COA without any marker is still legitimate but offers less analytical traceability.
How can I verify that a supplier sent leaf extract and not root extract?
Check three things on the COA: (1) the declared plant part — it should say "leaf" or "folium," not just "nettle"; (2) the marker compound — caffeoylmalic acid or chlorogenic acid point to leaf, while scopoletin or amino-acid content point to root; (3) if the COA includes an HPLC chromatogram, the peak profile can be compared against reference samples for the declared plant part.
References
[1] EMA/HMPC. Community herbal monograph on Urtica dioica L.; Urtica urens L., folium. EMA/HMPC/508015/2007. Read Document →
[2] EMA/HMPC. European Union herbal monograph on Urtica dioica L.; Urtica urens L., radix. Read Document →
[3] European Pharmacopoeia (Ph. Eur.), 10th edition. Urticae folium (monograph 01/2008:1897). Content: caffeoylmalic acid + chlorogenic acid ≥ 0.3 %, expressed as chlorogenic acid (dried drug).
[4] Koczkodaj S, Przybył JL, Kosakowska O, et al. Intraspecific Variability of Stinging Nettle (Urtica dioica L.). Molecules. 2023;28(3):1505. Read Paper →
[5] United States Pharmacopeia (USP). Powdered Stinging Nettle Extract monograph. Content: total amino acids ≥ 5.0 %; β-sitosterol ≥ 0.1 %; scopoletin ≥ 30 μg/g; DER 10:1; extraction solvent 60 % alcohol. Read Monograph →
[6] Chrubasik JE, Roufogalis BD, Wagner H, Chrubasik S. A comprehensive review on the stinging nettle effect and efficacy profiles. Part II: Urticae radix. Phytomedicine. 2007;14(7-8):568–579. Read Paper →
[7] Taheri Y, Suleria HAR, Martins N, et al. Stinging Nettle (Urtica dioica L.): Nutritional Composition, Bioactive Compounds, and Food Functional Properties. Molecules. 2022;27(16):5219. Read Paper →
[8] ESCOP Monographs. Urticae radix — Nettle Root (2nd ed. supplement, 2009); Urticae folium/herba — Nettle Leaf/Herb (2018). View ESCOP →
[9] Safarinejad MR. Urtica dioica for treatment of benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled, crossover study. J Herbal Pharmacother. 2005;5(4):1–11. Read Paper →
[10] Salari N, Barkhori F, Hosseinian-Far A, Ernst E. Urtica dioica for benign prostatic hyperplasia: a systematic review. J Herbal Medicine. 2025;50:100998. Read Paper →
[11] Riehemann K, Behnke B, Schulze-Osthoff K. Plant extracts from stinging nettle (Urtica dioica), an antirheumatic remedy, inhibit the proinflammatory transcription factor NF-kappaB. FEBS Lett. 1999;442(1):89–94.
[12] Roschek B Jr, Fink RC, McMichael M, Alberte RS. Nettle extract (Urtica dioica) affects key receptors and enzymes associated with allergic rhinitis. Phytother Res. 2009;23(7):920–926. Read Paper →
[13] Mittman P. Randomized, double-blind study of freeze-dried Urtica dioica in the treatment of allergic rhinitis. Planta Med. 1990;56(1):44–47. Read Paper →
[14] Aydın Köse A, Demonstir Gürsel G, Akalın Çiftçi G. Urtica dioica extract downregulates the gene expression of 5α-RII in HaCaT cells: possible implications against androgenic skin diseases. Clin Exp Health Sci. 2023;13:116–121. Read Paper →
[15] Baştürk A, Gürsel G, Akalın Çiftçi G, et al. Proprietary Herbal Extract Downregulates the Gene Expression of IL-1α in HaCaT Cells. Skin Pharmacol Physiol. 2018;31(5):268–276. Read Paper →
Reviewed by
Prof. Bingji MaScientific Adviser — medicinal plant science, phytochemistry, natural products quality
This article is provided for informational purposes for ingredient buyers and formulators. It does not constitute medical advice, health-claim guidance or regulatory counsel. Buyers should verify claim-substantiation and labelling requirements in their target market. Information is current as of September 2026; pharmacopoeial monographs may be updated — always consult the latest edition.
Need Assayed Nettle Leaf Extract?
Tell us your dosage form and target marker or extract ratio. We’ll recommend the right grade — ratio extracts from 10:1 to 50:1, or standardised β-sitosterol 0.8% by HPLC — and provide sample availability, COA and pricing.
